Warning! OUTDATED BROWSER DETECTED!   Please update your browser immediately for a better experience on this website. Learn More
  • Federal Cancer Moonshot Initiative Includes RSNA QIBA Profiles

    Two RSNA quantitative imaging biomarker profiles are aiding the Cancer Moonshot Initiative to eliminate cancer by accelerating research.

    January 13, 2017

    Two of RSNA’s Quantitative Imaging Biomarkers Alliance (QIBA) Profiles relevant to cancer have been referenced and supported by the federal Cancer Moonshot initiative to increase efforts to prevent, diagnose and treat cancer.

    Headed by Vice President Joe Biden, the 2016 initiative is designed to eliminate cancer by dramatically accelerating the pace of research.

    QIBA, which aims to improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices and time, has created profiles that define universal standards of operation. Specifically, the profiles establish comprehensive, systems-engineering, technical standards for image acquisition and processing.

    Added to the Cancer Moonshot website this month, the two completed QIBA Profiles relevant to cancer studies and treatments describe methods for obtaining accurate and reproducible 18F-fluorodeoxyglucose (FDG) PET/CT measurements and CT tumor volume measurements.

    “Having the QIBA process and QIBA Profiles recognized by the Moonshot Initiative provides considerably greater exposure for the QIBA concepts and products,” said Daniel C. Sullivan, MD, QIBA external relations liaison and professor emeritus in the Department of Radiology at the Duke University Medical Center, Durham, NC.

    Dr. Sullivan co-authored the blog, “Standards for Quantitative Imaging Biomarkers to Advance Research and Outcomes as part of the Cancer Moonshot,” posted on the Cancer Moonshot website describing how QIBA Profiles further a strategic goal of the initiative to unleash the power of data and enhance data sharing.

    “Use of these QIBA Profiles for standardized quantitative imaging will contribute significantly to improvements in the quality of cancer care, and to the development of more effective therapeutics in oncology,” Dr. Sullivan wrote in the blog co-authored by Roderic Pettigrew, PhD, MD, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB); Richard Cavanagh, PhD, director of the special programs office at the National Institute of Standards and Technology (NIST); and Shadi Mamaghani, PhD, scientific advisor to the NIBIB office of the director.

    “Having the post co-authored by senior members of the NIBIB and NIST adds external credibility to QIBA concepts and profiles,” Dr. Sullivan said.

    President Barack Obama announced the Cancer Moonshot during his 2016 State of the Union Address, calling on Biden to lead the $1 billion initiative with a stated mission to “to achieve a decade’s worth of progress in five years.”

    A task force was created to unite the federal government “in achieving the Moonshot’s mission through a focused effort to leverage federal investments, targeted incentives, private sector efforts, and patient initiatives, among other mechanisms,” according to the task force report.

    Daniel Sullivan, M.D.

    Web Extras